Here, we present the results of an 8-year prospective study that aimed to elucidate the precise role of eNAMPT in HCV infection, with a specific focus on cardiovascular events and malignancies by analyzing the NAMPT profile, including the eNAMPT levels and various NAMPT-associated SNPs, and adjusting for crucial confounders in CHC patients before and after anti-HCV therapy. The gene discussed is NAMPT; the disease is cryohydrocytosis.